Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.75
Bid: 41.00
Ask: 42.50
Change: 5.25 (14.38%)
Spread: 1.50 (3.659%)
Open: 37.00
High: 42.50
Low: 36.00
Prev. Close: 36.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal

Tue, 02nd Jan 2024 10:05

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

LungLife AI Inc, up 36% at 62.33 pence, 12-month range 19.00p-141.10p. The developer of clinical diagnostic solutions designed to address the early detection of lung cancer announces the successful validation of its LungLB test for indeterminate lung nodules. This is from a "prospective, multi-site clinical study in the clinically important small nodules patient group". The LungLB test is a blood-based tool used by clinicians to help with earlier diagnosis of lung cancer nodules. The diagnostic demonstrates a positive predictive value of 81% in distinguishing benign from cancerous lung nodules in patients with nodules smaller than 15 millimetres. This surpasses the current clinical standard of around 60%. According to LungLife, the results are sufficient for publication and the execution of its commercial programme for LungLB. The initial launch will be through an early access program offered from its California laboratory in the first quarter of 2024.

----------

Sareum Holdings PLC, up 19% at 71.00p, 12-month range 50.00p-149.00p. The pharmaceutical company's co-development partner CRT Pioneer Fund enters into a development and commercialisation licence for SRA737 with an unnamed US biopharmaceutical company. SRA737 is a clinical-stage oral, selective checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Sareum says an immediate upfront payment of USD500,000 is due to CRT Pioneer Fund, while an additional fee made up of up to USD1.0 million cash and 500,000 shares in the licensee company may be payable upon the sooner 12 months following the signing of the licencing agreement, or if the licensee company achieves certain commercial and material financing objectives. A further announcement regarding any future income, including any shares which may be issued, will be made "at the appropriate time".

----------

AIM - LOSERS

----------

Plexus Holdings PLC, down 15% at 17.94p, 12-month range 1.60p-31.40p. The oil and gas engineering services business completes an agreement with SLB to replace an existing surface production wellhead licence with a new licence over a wider field of use for USD5.2 million in cash. It says SLB acquires a perpetual royalty free license for Pos-Grip technology and HG seal technology plus any improvements, enhancements, or derivatives to the technology for surface wellhead production applications for all pressure and size ranges. Plexus says the licence scope includes oil and gas production and storage applications, as well as carbon dioxide storage and hydrogen storage, alongside water and cuttings reinjection. Plexus Chief Executive Officer Ben van Bilderbeek says: "This new licence agreement is a further validation of Plexus' [intellectual property] by this leading energy technology company and recognises the contribution our leak-proof POS-GRIP wellhead equipment can make to the oil and gas industry's [environmental, social and governance] and net zero goals."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
13 Sep 2022 08:13

CORRECT: Sareum notes US FDA approval of Bristol-Myers's Sotyktu

(Correcting that Bristol-Myers gained US FDA approval, not Sareum.)

Read more
12 Sep 2022 12:27

Sareum receives US US Food & Drug Administration approval for Sotyktu

(Alliance News) - Sareum Holdings PLC on Monday said the US Food & Drug Administration has approved Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor.

Read more
4 Jul 2022 11:23

IN BRIEF: Sareum notes updated payment terms after GSK buy of SRA737

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Notes that GSK PLC has completed its acquisition of Sierra Oncology Inc, the licence holder of SRA737, for USD1.9 billion. SRA737 was discovered and initially developed by scientists at the Institute of Cancer Research in collaboration with Sareum.

Read more
10 Jun 2022 11:19

Midatech Chair Rolf Stahel retires; Stephen Parker named as successor

(Alliance News) - Midatech Pharma PLC on Friday said that Chair Rolf Stahel plans to leave the board on June 20, and it named Stephen Parker as his successor.

Read more
13 Apr 2022 21:59

TRADING UPDATES: Sureserve gets new CFO; Sareum notes GSK buys Sierra

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
13 Apr 2022 19:46

TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Apr 2022 20:51

TRADING UPDATES: Pod Point wins BMW deal; Lamprell seals contract

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
16 Mar 2022 14:21

Sareum progresses Covid-19 and autoimmune treatment candidate

(Sharecast News) - Specialist drug developer Sareum Holdings updated the market on the development of its 'SDC-1801' - a potential Covid-19 and autoimmune disease treatment - towards first-in-human trials on Wednesday.

Read more
21 Feb 2022 18:13

TRADING UPDATES: Bank of Cyprus swings profit; Sareum loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
21 Feb 2022 15:55

UK shareholder meetings calendar - next 7 days

Tuesday 22 February 
Aberdeen Diversified Income & Growth Trust PLCAGM
Image Scan Holdings PLCAGM
Montanaro European Smaller Cos Trust PLCGM share issue
Wednesday 23 February 
Blencowe Resources PLCAGM
Gooch & Housego PLCAGM
Income & Growth VCT PLCGM re share subscription
Mobeus Income & Growth 2 VCT PLCGM re share subscription
Mobeus Income & Growth 4 VCT PLCGM re share subscription
Mobeus Income & Growth VCT PLCGM re share subscription
RWS Holdings PLCAGM
Tharisa PLCAGM
Titon Holdings PLCAGM
Thursday 24 February 
Bankers Investment Trust PLCAGM
IntegraFin Holdings PLCAGM
Victorian Plumbing Group PLCAGM
Friday 25 February 
Caledonian Trust PLCAGM
GRIT Investment Trust PLCAGM
Henderson Diversified Income Trust PLCGM re investment policy
On the Beach Group PLCAGM
Ruffer Investment Co LtdEGM re authority to issue shares
Monday 28 February 
Alternative Liquidity Fund LtdEGM
Ramsdens Holdings PLCAGM
Sareum Holdings PLCEGM re share consolidation
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
4 Feb 2022 14:37

IN BRIEF: Drug maker Sareum plans 50-into-1 share consolidation

IN BRIEF: Drug maker Sareum plans 50-into-1 share consolidation

Read more
17 Dec 2021 19:28

IN BRIEF: Sareum raises GBP1.6 million to advance inhibitor programmes

IN BRIEF: Sareum raises GBP1.6 million to advance inhibitor programmes

Read more
9 Dec 2021 14:43

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
23 Nov 2021 16:21

DIRECTOR DEALINGS: New MaxCyte chair buys USD220,000 in shares

DIRECTOR DEALINGS: New MaxCyte chair buys USD220,000 in shares

Read more
25 Oct 2021 08:48

Sareum full-year loss widens on research & development costs

Sareum full-year loss widens on research & development costs

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.